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ABSTRACT
Objectives To explore the predictive power of a risk
stratification method for people with hypertension based
on “essential” procedures (that is, available in
economically less developed areas of the world),
comparingitinthesamepopulationwiththeresultsgiven
by the method suggested by the 1999 World Health
Organization-InternationalSocietyofHypertension(WHO-
ISH) guidelines.
DesignProspectivecohortstudyofoutcomesaccordingto
cardiovascular risk profile at baseline.
SettingPrimarycareinapoorruralareaoftheEcuadorian
forest.
Participants 504 people with hypertension prospectively
monitored for a mean of 6.7 (SD 2.3) years.
Interventions Essential data included blood pressure,
medical history, smoking, age, sex, and diagnosis of
diabetes; the WHO-ISH methods additionally included
measurement of fasting blood glucose, total cholesterol,
and creatinine, urinalysis, and electrocardiography.
Main outcome measures Cardiovascular events and total
deaths.
Results With both methods there was a highly significant
association between the level of predicted risk and the
incidenceofcardiovasculareventsandoftotaldeaths:up
to three quarters of all cardiovascular events and two
thirdsofalldeathswerereportedamongpeopleclassified
as at high or very high risk with either method. The
predictive discrimination of the essential method is
comparable with the WHO-ISH with C statistics (95%
confidence interval) of 0.788 (0.721 to 0.855) and 0.744
(0.673 to 0.815), respectively, for cardiovascular events
and0.747(0.678to0.816)and0.705(0.632to0.778)for
total mortality.
Conclusions The risk stratification of patients with
hypertension with an essential package of variables (that
is,availableandpracticableevenintheeconomicallyless
developedareasoftheworld)servesatleastaswellasthe
more comprehensive method proposed by WHO-ISH.
INTRODUCTION
There is increasing emphasis in the major general and
specialised scientific journals on the burden of cardio-
vascular diseases in terms of mortality and morbidity
and of hypertension as a leading risk factor in low
income countries.
1-9 The instruments and strategies
proposed
10-14 to deal with these problems, however,
derive mostly from experimental and observational
studies produced in more developed countries.
Studies like INTERHEART provide important
support for the idea that the components of cardio-
vascular risk are substantially comparable across a
broad spectrum of populations and healthcare
systems.
1516 Cohort studies in low income countries,
aiming to assess not only the causal side of the risk but
the critical question of the transferability of measures
recommended to identify patients at risk and to
influence their clinical outcomes, are still rare.
17
This situation is likely to produce an important
cultural distortion in the perception and management
of problems by local and international health profes-
sionalsandplanners,furtheraggravatingthe impact of
well known socioeconomic inequalities.
1718 Countries
with restricted resources need a cost effective cardio-
vascular preventive strategy
19 so that candidates for
preventive interventions can be stratified by absolute
level of cardiovascular risk and priority given to those
at higher risk of complications.
20-22
We explored the predictive power of a risk
stratification method for hypertension based on
“essential” procedures (that is, available in good
community practice even in the economically less
developedareasoftheworld),comparingitinthesame
population with the results given by the method
suggested by the World Health Organization-Inter-
national Society of Hypertension (WHO-ISH)
guidelines
11 in an area that could be described as a
model of epidemiological transition
8 and where
hypertension has been carefully documented as the
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profile.
23
METHODS
The health district of Borbón in Ecuador is an area of
about 5000 km
2 almost completely covered by
equatorial forest. The population of about 25000
people, 85% black, 10% Amerindian Indios, and 5%
white, is scattered in 129 villages along three rivers,
which often serve as the only transport routes through
thearea;84%ofthepopulationisclassifiedaspoorand
34% extremely poor, and one third of the adults are
illiterate. The area is served by one hospital with 20
beds in Borbón, 12 health centres along the rivers
managed by non-specialised nursing staff, and a
network of 50 voluntary health “promotors” (“promo-
tores de salud”), with the occasional supervision from
rural medical doctors. Monthly meetings of all the
district health team workers are called regularly to
allowcloseandparticipatorymonitoringofthequality
of delivered care, with analysis of all relevant clinical
events.
Screening for hypertension and diagnostic investigation
Between1995and2001ascreeningprogrammeofthe
populationaged18andoverwassetuptoassessthesize
and impact of the risk of hypertension. Rural medical
doctors visited villages and measured blood pressure
withcalibratedaneroidsphygmomanometersinseated
patients. They recorded the lower of two values
measured 5 minutes apart, rounded to the nearest
5 mmHg. Allparticipantswith systolicblood pressure
≥140 mm Hg or diastolic ≥90 mm Hg were rechecked
the next day. The results of this screening programme
have been reported elsewhere.
23
The cohort of 1643 people with hypertension
(systolic blood pressure ≥140 mm Hg or diastolic
≥90mmHg,orboth,atthescreeningandthenextday,
or taking antihypertensive drugs) was prospectively
monitored, and all causes of death and major cardio-
vascular events (stroke, transient ischaemic attack,
myocardial infarction, heart or renal failure, and
vascular disease) were recorded. The rural medical
doctors diagnosed non-lethal cardiovascular events
during their periodic visits to the communities. All
deaths were included in a registry based on an
immediate postmortem form filled in by the local
nurse or health promoter. The rural medical doctors
subsequently defined cause of deaths with verbal
autopsies.
24-26
With the resources provided by an international
donation, between 1998 and 2001 a subset of
participants with hypertension underwent all the
laboratory and instrumental investigations recom-
mended by the World Health Organization (WHO)
and the International Society of Hypertension
(ISH).
1011 Tests included fasting blood glucose, total
cholesterol, and creatinine concentrations; urinalysis;
andelectrocardiography.Thelocalhospitallaboratory
could not measure plasma potassium concentrations.
Participants in the subset lived in the more accessible
villages because, in the absence of electricity, blood
samples had to be stored in a portable refrigerator and
had to be transferred as soon as possible to the local
hospital at Borbón. Complete laboratory data were
available for 504 of the 714 participants evaluated.
The results of the laboratory tests, with clinical
history, physical examination, and blood pressure,
served to estimate each participant’s future absolute
risk of major cardiovascular events, as suggested by
WHO-ISH guidelines.
11 These estimates are based on
*Age (men >55 and women >65), smoking, total cholesterol >6.47 mmol/l
†Evidence of left ventricular hypertrophy on electrocardiogram, proteinuria, or raised plasma creatinine (106.08–176.80 µmol/l)
‡Past or current symptoms of coronary disease, heart failure, cerebrovascular disease, vascular disease, renal disease
§Men >55 and women >65
<140/90
WHO-ISH method
No other risk factor or history of disease
1-2 risk factors* 
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Fig 1 | Stratification of cardiovascular risk to quantify prognosis: WHO-ISH andessentialmethods
Table 1 |Mainclinicalcharacteristicsatbaselineof504peoplewithhypertensioninvestigated
withWHO-ISHandessentialprognosticstratificationmethods.Figuresarenumbers(percentage)
ofparticipantsunlessstatedotherwise
Data
Age (years):
Mean (SD) 55.5 (14.4)
>55 for men or >65 for women 164 (33)
Sex (female) 337 (67)
Race (black) 470 (93)
Systolic and diastolic blood pressure (mm Hg):
<140/90 72 (14)
140-159/90-99 126 (25)
160-179/100-109 133 (27)
≥180/110 173 (34)
Mean (SD) 159.7 (31.1)/97.4 (15.3)
Current smoking 35 (7)
Total cholesterol >6.47 mmol/l 45 (9)
Proteinuria 10 (2)
Raised plasma creatinine (106.08-176.80 µmol/l) 37 (7)
Evidence of left ventricular hypertrophy on ECG 12 (2)
Diabetes mellitus 30 (6)
Cerebrovascular disease 14 (3)
Coronary disease 2 (0.4)
Heart failure 6 (1)
Renal failure 1 (0.2)
Vascular disease 0
ECG=electrocardiogram.
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and history of diseases (age, sex, family history of
premature cardiovascular disease, smoking, choles-
terol,diabetes,targetorgandamage,associatedclinical
conditions)(fig1).Theruralmedicaldoctorsdiagnosed
associated clinical conditions (cerebrovascular or
coronary diseases, heart and renal failure, vascular
disease) on the basis of clinical history, physical
examination, and, when available, clinical record, as
suggested by the WHO-ISH 1999 guidelines.
11 We
couldnotevaluatehypertensiveretinopathybecauseof
thelackofequipmentandtechnicalcompetence,anda
family history of premature cardiovascular disease
could not be assumed to be retrievable information.
This should not have altered the predictive power of
theWHO-ISHmethodasgeneralisedorfocalnarrow-
ing of the retinal arteries has low specificity
27 and has
therefore been dropped as target organ damage in the
2003 WHO-ISH guidelines,
28 and advanced retino-
pathy is usually associated with severe hypertension,
that is in itself a high risk condition. Moreover, the
prevalence of a family history of premature cardio-
vasculardiseaseinanadultpopulationinthetransition
phase is expected to be low.
As the 1999 WHO-ISH guidelines do not suggest
specific electrocardiographic criteria for left ventricu-
larhypertrophy,weadoptedtheFraminghamcriterion
for left ventricular hypertrophy as providing a better
score of predictive power.
29 We modified the original
WHO-ISH stratification table to include all those with
known hypertension, includingthose taking treatment
whohadnormalbloodpressurereadingsonthedayof
the laboratory test (fig 1).
As the laboratory and instrumental investigations
recommended by the WHO-ISH are not usually
available for people living in this poor region of the
equatorial forest, in the same population evaluated
according to the method suggested by WHO-ISH
guidelines we studied the predictive power of a
simplified risk stratification method based only on the
data available even in this economically underdeve-
lopedarea.Inadditiontobloodpressure,thisessential
method includes age, smoking, diabetes (which in this
population is usually self diagnosed by tasting urine),
and associated clinical conditions (fig 1).
Wecomparedthetworiskpredictionmethodsusing
cardiovascular events (the first non-lethal cardio-
vascular event or cardiovascular death) as the primary
outcome and total mortality as secondary outcome.
Statistical analysis
Descriptive data are expressed as counts (percentages)
for categorical data and as means (SD) for continuous
variables, as appropriate. We measured concordance
between the two methods in individual risk stratifica-
tionbytheweightedκstatistic.Differencesintherateof
eventsaccordingtoriskcategorieswereevaluatedwith
theMantel-Haenszeltestforlinearassociation.Plotsof
the Kaplan-Meier estimate of the survival curves
according to the cardiovascular risk categories of the
two methods are shown for cardiovascular events and
totaldeaths.Survivalplotsruntothemeanfollow-upof
seven years. We constructed two multivariable Cox
proportionalhazardsmodelsforcardiovascularevents
for each method, adjusting for four classes of blood
pressure and four categories of other risk factors and
historyofdisease(fig1).Tocomparethepredictivityof
the two stratification methods we used receiver
operating characteristic (ROC) curves based on the
same variables as the Cox regression models. These
curves are the plot of the true positive rate (sensitivity)
in relation to the false positive rate (100−specificity).
30
The area under the curve, which is equivalent to the C
statistic, provides a summary measure of the accuracy
Table 2 |Riskfactors*(otherthanbloodpressure)andcardiovascularriskestimatedwithand
withoutlaboratoryinvestigations†.Figuresarenumbers(percentage)ofparticipants
With laboratory investigations Without laboratory investigations
No other risk factors 235 (47) 285 (57)
1-2 risk factors 167 (33) 168 (33)
≥3 risk factors or TOD‡ or diabetes 80 (16) 29 (6)
Associated clinical conditions§ 22 (4) 22 (4)
Stratification of total cardiovascular risk:
Very low risk 33 (6) 47 (9)
L o wr i s k 9 4( 1 9 ) 9 9( 2 0 )
Medium risk 160 (32) 157 (31)
High risk 102 (20) 104 (21)
Very high risk 115 (23) 97 (19)
*Age (men >55 and women >65), current smoking, total cholesterol >6.47 mmol/l.
†Electrocardiography, serum total cholesterol, serum creatinine, urinalysis for protein.
‡Target organ damage (TOD) included evidence of left ventricular hypertrophy on electrocardiogram, proteinuria,
raised plasma creatinine (106.08-176.80 µmol/l).
§History or current symptoms of coronary disease, heart failure, cerebrovascular disease, vascular disease,
renal disease.
Table 3 |Concordance*betweenWHO-ISHandessentialprognosticstratificationmethodsindefiningindividualglobal
cardiovascularrisk
Cardiovascular risk according to
essential method
Cardiovascular risk according to WHO-ISH methods
Total Very low Low Medium High Very high
Very low 33 5 9 0 0 47
Low 0 89 6 4 0 99
Medium 0 0 145 12 0 157
High 0 0 0 86 18 104
Very high 0 0 0 0 97 97
Total 33 94 160 102 115 504
*Weighted κ=0.9023.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 8of the diagnostic test, which can also be thought of as
howwellthetestdistinguishedbetweenthosewithand
without outcomes (cardiovascular events or death).
The curves were calculated up to a maximum of seven
years. To assess the diagnostic performance of the two
methods of risk stratification we compared predicted
cardiovascular risk (medium and over, high and over,
or very high) with observed outcomes (incidence of
cardiovascular events and total deaths during follow-
up), calculating the sensitivity and specificity. All
statistical analyses were done with SAS (version 9),
and all tests were done at the 5% significance level.
RESULTS
Table 1 shows the main characteristics at baseline of
the 504 participants with hypertension evaluated
according to both methods. Most had known about
their hypertension for many years (5-10 years for 172
(34%) and >10 years for 119 (24%)). Only 82 patients
(16%) were being treated with antihypertensive drugs,
and 150 (30%) had received advice on non-pharmaco-
logical measures (such as reduction in salt intake). Of
the504patients,86%hadbloodpressure≥140/90mm
Hg and 34% had blood pressure ≥180/110 mm Hg.
Fifty six (11%) had evidence of target organ damage
(evidence of left ventricular hypertrophy on the
electrocardiogram, proteinuria, or slightly raised
plasma creatinine concentrations). Associated clinical
conditions (history or current symptoms of coronary
disease,heartfailure,cerebrovasculardisease,vascular
disease,renaldisease)werereportedin22(4%),mainly
cerebrovascular events (n=14) and heart failure (n=6).
Stratification by absolute level of cardiovascular risk
Table 2 shows the distribution of participants
according to cardiovascular risk factors other than
blood pressure, target organ damage, and associated
clinical conditions, evaluated with and withoutlabora-
tory investigations. As expected, laboratory investiga-
tionsincreasedtheproportionofparticipantsidentified
with three or more associated cardiovascular risk
factors, target organ damage, or diabetes. In 433
patients (86%), however, the two methods were
concordant in weighting the “other risk factors and
disease history” with a weighted κ value of 0.764.
As expected, laboratory results identified a larger
proportion of participants classified at higher risk
(table 2). In 450 (89%), however, the two methods
agreed in stratifying total cardiovascular risk with a
weightedκ valueof 0.902(table 3). Inonly 16 patients
outof217(7%)didtheessentialmethodnotconfirmthe
high or very high risk defined by the WHO-ISH
method (table 3).
Incidence of cardiovascular events during follow-up
according to risk prediction
On 31 December 2007 we examined the rates of
cardiovascular events and total deaths for all 504
patientswithhypertension.Duringameanfollow-upof
6.7 (SD 2.3) years (range 12 days-9.7 years), 76 (15%)
had a cardiovascular event and 74 (15%) died. Thirty
two had one or more strokes (19 fatal), 30 had one or
more episodes of heart failure (18 fatal), 14 had one or
more transient ischaemic attacks, four died suddenly,
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Fig2 | Kaplan-Meiersurvivalcurvesforcardiovascularevents(firstnon-lethalcardiovasculareventorcardiovasculardeath)andfor
total deaths according to cardiovascular risk categories of WHO-ISH and essential methods
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andonehadfatalrenalfailure.Fourteendiedfromnon-
cardiovascular causes and 16 of unknown causes.
The proportion of participants with cardiovascular
eventswas significantly associatedwith baselineblood
pressure:respectively7%,11%,10%,and25%inthose
with normal blood pressure (<140/90 mm Hg), mild
(140-159/90-99 mm Hg), moderate (160-179/100-
109mmHg),andsevere(≥180/110mmHg)hyperten-
sion (P<0.001 for trend). The proportion with cardio-
vascular events was also significantly associated with
the four categories of other risk factors and history of
disease considered in the WHO-ISH method (7%,
19%, 15%, and 68%, P<0.001 for trend) and the
essentialmethod(6%,21%,24%,and68%,P<0.001for
trend).
Multivariate Cox analyses confirmed that in this
population the criteria adopted by both methods
(blood pressure classes and categories of other risk
factors and disease history) were significantly asso-
ciatedwiththeincidenceofcardiovascularevents(data
notshown).KaplanMeiersurvivalcurvesinpatientsat
very low, low, medium, high, and very high cardio-
vascular risk according to both methods indicated a
highly significant association between the level of
predicted risk with both methods and the incidence of
cardiovascular events (log rank test, P<0.001) (fig 2).
The ROC curves show that the predictive discrimina-
tion of the essential method was comparable with that
of the WHO-ISH method with C statistics 0.788 (95%
confidenceinterval0.721to0.855)and0.744(0.673to
0.815), respectively (fig 3).
Table 4 shows the sensitivity and specificity of both
methods against different risk thresholds for cardio-
vascular events. There were no significant differences
between the two methods at any risk threshold for all
the criteria.
Up to three quarters of all participants with cardio-
vascular events were classified as at high or very high
risk under either stratification methods: 57 out of 76
(75%) among the 217 identified at risk with the WHO-
ISH criteria and 56 out of 76 (74%) among the 201
identified at risk with the essential package.
Only two of the 76 cardiovascular events were in
participants who were classified according to the
essential method as at lower risk than according to
the WHO-ISH method: one was a patient classified
mediuminsteadofhighriskandtheotherwasclassified
as high risk instead of very high.
The results did not change substantially when we
restricted the analyses to the 357 patients with blood
pressure ≥140/90 mm Hg who were not taking
antihypertensive drugs at baseline. The predictive
discriminationoftheessentialmethodwascomparable
with that of the WHO-ISH, with C statistics 0.759
(0.667 to 0.851) and 0.715 (0.619 to 0.811), respec-
tively.
The use of electrocardiographic criteria for the
detection of left ventricular hypertrophy by a more
sensitive method than the Framingham criterion, such
astheRomhilt-EstesandPerugiascoreortheSokolow-
Lyon and Cornell voltages,
31 would reduce the
predictive discrimination of the WHO-ISH method:
C statistics 0.739 (0.668 to 0.810), 0.725 (0.652 to
0.798), 0.724 (0.651 to 0.797), and 0.723 (0.650 to
0.796), respectively.
Total mortality during follow-up according to risk
prediction
The percentages of all deaths in patients at very low,
low, medium, high, and very high cardiovascular risk
were 3%, 6%, 10%, 16%, and 30% according to the
WHO-ISH method and 4%, 6%, 10%, 15%, and 35%
according to the essential method. As for cardio-
vascular events, even with total deaths as outcome,
both stratification methods showed a significant
association between the level of predicted risk and
mortality (log rank test, P<0.001) (fig 2); similar
predictive discrimination with C statistic 0.705 (0.632
to 0.778) for the WHO-ISH method and 0.747 (0.678
to 0.816) for the essential method (fig 3); and
comparable sensitivity and specificity (table 4).
DISCUSSION
A simplified method for risk stratification of patients
with hypertension based on variables that can be
classified as essential (because of their affordability,
applicability, and reliability even in the economically
less developed areas of the world) performs at least as
well as the more comprehensive method recom-
mended by WHO-ISH guidelines.
11 Among the high
risk patients identified without any laboratory or
instrumental examination we recorded three quarters
of all the cardiovascular events occurring during a
seven year follow-up (sensitivity 75% v 76% for the
WHO-ISH method). The specificity of the simplified
methodwasalsoclosetothatoftheWHO-ISHcriteria.
Hypertension is increasingly recognised as a major
cause of mortality and morbidity in low income
countries, where its complications arise at an earlier
Table 4 |Sensitivityandspecificity(95%confidenceinterval)oftwostratificationmethodsat
variouscardiovascularriskthresholds
Risk level
≥ Medium ≥ High Very high
Cardiovascular events
Sensitivity:
WHO-ISH 91.0 (84.2 to 97.9) 76.1 (65.9 to 86.3) 55.2 (43.3 to 67.1)
Essential 91.0 (84.2 to 97.9) 74.6 (64.2 to 85.0) 53.7 (41.8 to 65.7)
Specificity:
WHO-ISH 27.7 (23.5 to 31.9) 62.0 (57.5 to 66.6) 82.2 (78.6 to 85.7)
Essential 32.0 (27.7 to 36.4) 65.5 (61.0 to 69.9) 86.0 (82.8 to 89.3)
Total deaths
Sensitivity:
WHO-ISH 90.0 (83.0 to 97.0) 67.2 (56.1 to 78.1) 45.7 (34.0 to 57.4)
Essential 88.6 (81.1 to 96.0) 65.7 (54.6 to 76.8) 44.3 (32.7 to 55.9)
Specificity:
WHO-ISH 27.7 (23.4 to 31.9) 60.8 (56.2 to 65.4) 80.9 (77.2 to 84.6)
Essential 31.8 (27.4 to 36.2) 64.3 (59.8 to 68.8) 84.8 (81.4 to 88.2)
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6-9 The most cost
effective and nowadays universally recommended
approach for the treatment of hypertension should be
based on the absolute risk of cardiovascular
disease.
71011 Methods for the identification of high
risk patients should be simple, reproducible, easily
accessible, and low cost, especially in developing
countries.
19 The scheme for stratifying the global risk
in hypertension was formulated by WHO-ISH in
1999
11 and subsequently updated and revised.
2832 No
dataareavailable,however,ontherealapplicabilityof
this method in developing countries.
Strengths and limitations
Our findings have the advantage of reflecting real life
conditions, where the clinical outcomes include all the
relevant field variables that can arise over a follow-up
that was particularly long for a difficult and deprived
setting of life and care, although we might have
underestimated the overall rate of cardiovascular
events because of the difficulties of doing instrumental
and laboratory tests in this setting. A better classifica-
tion of cardiovascular events, however, should not
have influencedthe results of the comparisonbetween
the two risk stratification approaches. Also, to over-
come this possible limitation, we included total deaths
in the evaluation of the prognostic power of the two
methods.
Inaremoteruralregionofalowincomecountrythe
WHO-ISHcriteriawouldbehardtoapplyineveryday
practice.
19Someofthevariablescouldnotbemeasured
either because of the lack of equipment or technical
skills(forexample,examinationoftheopticfundus)or
the unavailability or unreliability of information
(family history of premature cardiovascular events).
In our study we were able to carry out systematic
electrocardiography and biochemical analyses
because of an ad hoc research grant that helped to
overcome logistic and organisational barriers. In
routine practice people with hypertension should
attend the nearest local hospital to be examined,
which might require a full day of difficult travel (such
as river navigation), affordable by only a minority of
people. In regions with limited medical staff the
simplified approach for first line screening of people
athigherriskcouldbeeasilyusedbynon-medicalstaff.
Theapplicabilityofthismethodbythe“promotoresde
salud” is currently being assessed in the health district
of Borbón.
Comparison with other studies
Though we know of no other similar studies, the
problemsdescribedherearelikelytoberepresentative
of the logistic and economic barriers in many other
rural areas of Latin America and many other low
income countries. Moreover, although our study
population was mainly made up of black people with
high and often untreated hypertension, the results in
terms of feasibility and predictive accuracy of the
proposed simplified method for stratifying cardio-
vascular risk should be easily transferable and applic-
able in other settings at a similar stage of the
epidemiological transition.
89
Implications
Operationally,theresourcesneededfortheprocedures
included in the “standards” could be drastically
reduced, thus allowing broader coverage of the
population as well as closer care of those at highest
risk or thosealready disabled.For example,nowadays
in the district of Borbón the cost to a patient for the
laboratory tests recommended by WHO-ISH is
equivalent to the cost of almost two years’ treatment
with antihypertensive drugs.
Fromthepublichealthpointofview,ourdatadonot
support the consolidated idea of a direct proportion
betweenmoresophisticatedandcostlyapproachesand
better care. While the best existing knowledge must
certainly be kept in mind, the approach we adopted
highlights the priority and the need to put the issue of
practicable care in the forefront. Time should not be
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total deaths according to WHO-ISH and essential methods
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recommendations but in the field, assessing the
outcomes of due and possible care and producing
original knowledge of the degree of effectiveness (or
epidemiological efficacy) of essential practices (that is,
recommended and transferable).
Thirty years ago, the WHO report on essential
drugs
33 was conceived as a tool to assure that most
peoplecouldhaveaccesstodrugsaspartoftheirrights
tolife.Governingbodieswerechallengedtotransform
theessentialdrugslistintoconcretehealthpolicies.We
now also need essential prognostic tools, but there are
few field projects that prospectively monitor the
outcomes of affordable (not simply recommended)
diagnostic practices.
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